Application is supported by results from the DEVOTE study, which suggested that two doses of Spinraza (nusinerse) 50 mg taken ...

By clicking “Accept All Cookies”, you agree to the storing of cookies on your device to enhance site navigation, analyze site ...

The parents of two-year-old Aakriti Singh diagnosed with Spinal Muscular Atrophy – SMA type-1, are worried about her next ...

SMA type 1 often results in death by the age of 2 without breathing support. Life expectancy for SMA type 2 varies but is usually between 20 and 40 years. SMA types 3 and 4 typically don’t ...

Zolgensma can be used in patients with inherited mutations affecting genes known as SMN1, who have either been diagnosed with SMA type 1 - the most severe type - or have up to 3 copies of ...

Nonadherence by SMA patients to their prescribed regimen of Evrysdi is linked to higher healthcare costs, a real-world U.S.

Patients with spinal muscular atrophy (SMA) type 2 showed improved motor ability when treated with intrathecal onasemnogene ...

European approval is based on the completed phase 3 STR1VE-US and phase 1 START trials that tested the efficacy and safety of a one-time IV infusion of Zolgensma in symptomatic SMA Type 1 ...

Positive results from its Phase III STEER study mean Novartis could boost sales of its OAV101 IT drug for spinal muscular ...